EGFR and neoplasm: Moreover, pre-clinical studies suggested that MK2206, in combination with other targeted therapies like mTOR inhibitors or Epidermal Growth Factor Receptor (EGFR) inhibitors, can enhance anti-tumor activity and overcome resistance to single-agent treatments [21,22].